10x Genomics, Inc.· TXG
🇺🇸 US · MidBroad USNASDAQ
- Price
- $47.86
- Day
- +1.81%
- Mkt Cap
- $6.08B
- 52W Range
- $11.16 – $50.34
- Volume
- 2.53M
- Beta
- 2.04
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read full article
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
Collaboration aims to identify biomarkers predictive of treatment response across multiple cancer types using 10x's single cell and spatial platforms PLEASANTON, Calif., July 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Lausanne University Hospital (CHUV), one of Switzerland's leading academic medical centers, to advance research in diagnostic applications of single cell and spatial technologies for cancer care.
Read full article
Amova Asset Management Americas Inc. cut its holdings in shares of 10x Genomics (NASDAQ: TXG) by 7.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,104,178 shares of the company's stock after selling 381,975 shares during the period. 10x
Read full article
Mitesco (OTCMKTS:MITI - Get Free Report) and 10x Genomics (NASDAQ: TXG - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation. Profitability This table compares Mitesco and 10x Genomics' net
Read full article
PLEASANTON, Calif., July 15, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will report financial results for the second quarter ended June 30, 2026 after market close on Thursday, August 6, 2026.
Read full article